WO2002095418A2 - Procede destine a examiner et a diagnostiquer la sante dermatologique - Google Patents

Procede destine a examiner et a diagnostiquer la sante dermatologique Download PDF

Info

Publication number
WO2002095418A2
WO2002095418A2 PCT/US2002/011344 US0211344W WO02095418A2 WO 2002095418 A2 WO2002095418 A2 WO 2002095418A2 US 0211344 W US0211344 W US 0211344W WO 02095418 A2 WO02095418 A2 WO 02095418A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
subject
analyte
vitamin
amount
Prior art date
Application number
PCT/US2002/011344
Other languages
English (en)
Other versions
WO2002095418A3 (fr
Inventor
Gregory Skover
Original Assignee
Johnson & Johnson Consumer Companies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/920,593 external-priority patent/US6840910B2/en
Priority claimed from US09/920,136 external-priority patent/US6855117B2/en
Priority claimed from US09/920,266 external-priority patent/US6790179B2/en
Application filed by Johnson & Johnson Consumer Companies, Inc. filed Critical Johnson & Johnson Consumer Companies, Inc.
Priority to EP02733970A priority Critical patent/EP1412756A2/fr
Priority to CA002447323A priority patent/CA2447323A1/fr
Publication of WO2002095418A2 publication Critical patent/WO2002095418A2/fr
Publication of WO2002095418A3 publication Critical patent/WO2002095418A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A45—HAND OR TRAVELLING ARTICLES
    • A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
    • A45D44/00—Other cosmetic or toiletry articles, e.g. for hairdressers' rooms
    • A45D2044/007—Devices for determining the condition of hair or skin or for selecting the appropriate cosmetic or hair treatment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors

Definitions

  • the present invention relates to a method of examining, diagnosing, or treating the skin of a subject.
  • Dermal interstitial fluid is a clear, water-like fluid present between the cells in the living skin tissues (i.e., epidermis and dermis) under the stratum corneum.
  • the composition of the interstitial fluid is substantially free of blood cells, but does contain small molecules and proteins. Interstitial fluid both transports nutrients (e.g., glucose) from the blood to the skin cells and removes cellular metabolic wastes
  • urea urea
  • Various components of the interstitial fluid are in equilibrium with living cells in both the epidermis and dermis as well as macromolecular structures located in the subcutaneous tissue.
  • the invention features a method of examining skin health in a subject, the method including the steps of: accessing a sample of interstitial fluid from the skin of the subject; and measuring the amount of a skin analyte in the sample.
  • the invention features a method of examining skin health in a subject, the method including measuring in vitro the amount of a skin analyte in a sample of interstitial fluid accessed from the skin of the subj ect .
  • the invention features a method of diagnosing the skin health in a subject, the method including the steps of: (a) accessing a sample of interstitial fluid from the skin of the subject; (b) measuring the amount of a skin analyte in the sample; and (c) comparing the amount of the skin analyte to a reference standard.
  • the invention features a method of diagnosing the skin health in a subject, the method including the steps of: (a) measuring in vitro the amount of a skin analyte in a sample of interstitial fluid obtained from the skin of the subject; and (b) comparing the amount of the skin analyte to a reference standard.
  • the invention features a method of treating the skin of a subject, the method including the steps of: (a) accessing a sample of interstitial fluid from the skin of the subject; (b) measuring the amount of a skin analyte in the sample; and (c) applying a skin care product to the subject to alter the amount of the skin analyte in the skin of the subject.
  • the invention features a method of treating the skin of a subject, the method including the steps of: (a) measuring in vitro the amount of a skin analyte in a sample of interstitial fluid obtained from the skin of the subject; and (b) applying a skin care product to the subject to alter the amount of the skin analyte in the skin of the subject.
  • the invention features a method of distributing a skin care product to a subject, the method including the steps of: (a) obtaining a sample of interstitial fluid from the skin of the subject; (b) measuring the amount of a skin analyte in the sample; and (c) distributing a skin care product to the subject to alter the amount of the skin analyte in the skin of the subj ect .
  • the invention features a method of distributing a skin care product to a subject, the method including the steps of: (a) measuring in vitro the amount of a skin analyte in a sample of interstitial fluid obtained from the skin of the subject; and (b) distributing a skin care product to the subject to alter the amount of the skin analyte in the skin of the subject .
  • the method comprises creating a opening in the stratum corneum of the skin of the subject and accessing said sample through said opening.
  • the opening is created with a needle, a blade, a laser, or an electric arc.
  • the sample is extracted through said opening under negative pressure.
  • the skin analyte is a vitamin such as vitamin C, an immunoglobulin, an insulin-like growth factor, an interleukin, an interleukin receptor antagonist, or a metalloproteinase .
  • What is meant by "examining skin health” is obtaining information regarding the current biological condition of the skin.
  • Such information may provide insight into the current health of the skin (e.g., to determine whether certain cosmetic or pharmaceutical skin treatments are necessary) as well as provide insight regarding the response of the skin to external trauma or treatment.
  • the information is obtained on a periodic basis, e.g., once a year, once a month, once a week, or once a day, to continually monitor skin health.
  • skin analyte is a chemical entity present in the interstitial fluid of the skin that either participates in the biological processes of the skin or is a product of such processes.
  • the skin analyte is an endogenous substance.
  • the skin analyte is- an exogenous substance that entered the skin intentionally or unintentionally, which may exert desirable or undesirable biological effects on the skin.
  • the present invention relates to a method of examining skin health in a subject by obtaining a sample of interstitial fluid from the skin of said subject (e.g., a mammalian subject such as a human) .
  • a sample of interstitial fluid is the clear fluid present between the cells in the living epidermis and dermis, which is substantially free of blood cells.
  • the method of obtaining such sample of interstitial fluid comprises creating an opening in the stratum corneum of the skin of said subject and obtaining said sample through the opening.
  • the opening is also within the epidermis of the subject.
  • the opening is also within the dermis of said subject.
  • the opening results in minimal residual tissue damage in order not to alter the composition of the interstitial fluid. For example, creating a blister on the skin and then sampling the resulting interstitial fluid in the blister is not preferred.
  • about 1 to about 1000 openings are created in the skin of the subj ect , such as about 2 to about 50 openings.
  • the width of the opening is about 1 to about 500 microns, such as about 50 to about 250 microns.
  • the depth of the opening is about 50 to about 500 microns, such as about 75 to about 200 microns. The number and size of openings will depend on the subject being treated and the area of skin being analyzed.
  • the opening is created by a mechanical device.
  • mechanical devices include, but are not limited to, hollow and solid needles, micro styluses, trochars, blades, and lancets.
  • such devices have an external diameter or width of up to 1 mm, such as bout 10 and about 200 microns.
  • the mechanical device creates an opening either by piercing or scraping the stratum corneum. Examples of such mechanical devices can be found in PCT Patent Applications Nos.
  • the opening is created by a heating device.
  • heating devices include, but are not limited to, heated elements (e.g., an ohmic heating element such as a wire heated by electric current), lasers, and focused light beams of multiple wavelengths.
  • a dye that exhibits an absorption of light over the emission range of the laser or focused light beam is first applied to the skin such that the dye is heated sufficiently to create the opening. Examples of such heated elements, laser, and focuses light beams are disclosed in U.S. Patent Nos. 5,885,211, 5,155,992, and 6,056,738; and PCT Patent Application Nos. WO 99/40848, WO 99/27852, WO 99/20181, WO 97/42888, and WO 99/59485.
  • a beam of sonic energy is used to create the opening in the stratum corneum.
  • sonic devices and/or the use thereof to create openings in the stratum corneum are disclosed in U.S. Patent Nos. 5,445,611, 5,458,140, and 5,885,211.
  • a short pulse of electricity is used to create the opening in the stratum corneum. Examples of such use can be found in U.S. Patent No. 5,885,211.
  • a high pressure jet of a fluid, gas, or particulate is used to create the opening in the stratum corneum. Examples of the use of such high pressure jets can be found in US Patent No. 5,885,211.
  • an electric arc is used to create the pore in the stratum corneum.
  • Examples of such a device and the use of such a device to create an opening in the stratum corneum is disclosed in PCT Patent Application No. WO 01/13989.
  • electromagnetic radiation is used to disrupt the stratum corneum in order to create openings to access the interstitial fluid. Examples of such uses are set forth in Tope, Dermatol Surg 25:348-52 (1999) .
  • a suction blister is created on the skin, and the roof of the blister is pieced or removed to obtain the interstitial fluid within the blister.
  • An example of such a device and the use of this device to so obtain interstitial fluid is disclosed in Evedman, Pharm. Res., 15:6, 883-8 (1998) .
  • a sample of the subject's interstitial fluid is extracted by the use of negative pressure.
  • examples include various means known in the art, which include, but are not limited to: a mechanical suction device with the structure similar to a syringe; a manual mechanical suction device using a piston and a series of one-way valves with the working mechanism similar to commercial apparatuses such as MityVac II® vacuum pump (Prism Enterprises, San Antonio, TX, USA) and Aspivenin® (ASPIR, Sannois, France) ; a small size motor- driving suction/vacuum pump; a rubber pipeting suction bulb such as Bel-Bulb® Pipettor (Bel-Art Products, Inc., NJ, USA) and Welch® Suction Cup Electrode (Hewlett Packard, Rockville, MD, USA) ; a pre-manufactured vacuum chamber with the working mechanism similar to the Vacumtainer® (Becton, Dickinson and Company, Franklin Lakes,
  • Kneading or vibration or pressure mechanism may be used together with such suction devices to manipulate ' the skin around the opening to facilitate the collection of the interstitial fluid.
  • Example of such methods can be found in PCT Patent Application Nos. WO 97/428882 and WO97/08987.
  • a method of heating the skin around the opening may also be used, with or without suction, to facilitate the interstitial fluid collection.
  • Other methods of enhancing the extraction of interstitial fluid include iontophoresis as well as the use of sonic energy and ultrasound. Such an example can be found in PCT
  • the suction force may be within the range of 5- 75 cm Hg (e.g., 20-60 cm Hg) .
  • interstitial fluid can be extracted using an osmotic pressure by contacting the skin (e.g., skin in which the stratum corneum has been compromised as stated above) with a hygroscopic material such as glycerin, glycols such as polyethylene glycols and polypropylene glycols, urea, or polyvinylidone.
  • a hygroscopic material such as glycerin, glycols such as polyethylene glycols and polypropylene glycols, urea, or polyvinylidone.
  • Other examples include inserting an optical fiber within the opening to register light interaction with an analyte. See PCT Patent Application No. WO 99/07277.
  • a permeation enhancer is used to enhance the extraction of the interstitial fluid.
  • permeation enhancers include, but are not limited to, dimethyl sulfoxide, sodium hydroxide, dimethylamino ethanol, butanol, propylene glycol, oleic acid, and azone. Examples of permeation enhancers are disclosed in U.S. Patent Nos. 5,458,140, 5,445,611, 4,775,361, and 4,863,970.
  • the interstitial fluid is collected in the same device that created in the opening in the stratum corneum (e.g., a device that comprises (i) a mechanical device or a heating device to create the opening in the stratum corneum and (ii) a vacuum device to extract a sample of the interstitial fluid) .
  • the device is further capable of measuring the concentration of the skin analyte (s) in the collected sample as described below (e.g., using a sensor for the analyte) .
  • the concentrations of a skin analyte (s) in the interstitial fluid can be measured with standard analytical methods known in the art such as assays based on enzymatic reaction, antibody interaction, ion-selective electrode, oxidation-reduction electrode; infrared (IR) , ultraviolet (UV) spectrophotometry, colorimetry, gene array technology, and gene amplification.
  • analysis of the biological substances of interest in the interstitial fluid may be performed through the opening created by placing an analytical instrument (e.g., an infrared or ultraviolet spectrophotometer) directly over the opening, without actually extracting the interstitial fluid out of the skin.
  • an analytical instrument e.g., an infrared or ultraviolet spectrophotometer
  • the present invention relates to a method of measuring the amount of biochemical component in said sample (herein referred to as a "skin analyte”) .
  • the skin analyte is substance which will provide feedback as to the health of the skin, e.g., provide a marker for possible skin disorders such as but not limited to: intrinsic skin aging, wrinkles, acne, photodamage, rosacea, scars, hypertrophic scars, keliods, stretch marks or striae distensiae, psoriasis, nutrient status, anti-oxidant status, energy status, oxygen status, eicosanoid staus, leukotriene status, pruritus, ehlers- danlos syndrome, scleroderma, post inflammatory hyperpigmentation, melasma, alopecia, poikiloderma of civatte, viteligo, skin cancers, skin dyschromas or blotchy pigmentation.
  • the skin analyte is predominantly found in the skin.
  • skin analytes include, but are not limited to, enzymes such as the family of matrix metalloproteinases such as MMP 1 through MMP-13, stromolysin, elastase, glucosylceramide synthetase, and glutathione peroxidase; antibodies that demonstrate status of a skin disorder; macromolecules such as the collagen family of proteins such as collagen I through collagen XVIII, elastin, keratins, and glycosaminoglycans ; the integrin family of matrix receptors such as integrins type alpha 2 through 10 and integrins type beta 1 through 8 ; cytokines such as insulin-like growth factors such as IGF-1 and tissue inhibitor of matrix proteinases; and derivatives thereof .
  • enzymes such as the family of matrix metalloproteinases such as MMP 1 through MMP-13, stromolysin, elastase, glucosylcer
  • Other skin analytes include, but are not limited to, enzymes such as B-galactosidase, ALA and ASP transferase, protein kinase C, NO synthetase, ornithine decarboxylase, ubiquitin-conjugating enzymes, phosolipid hydroperoxide , death associated protein kinase, DAP kinase or other serine-threonine kinases involved in cellular apoptosis, and superoxide dismutase; macromolecules such as hyaluronic acid, fibronectin, fibrin, basement membrane components including laminin and type IV collagen; cytokines such as platelet derived growth factor, keratinocyte growth factor, epidermal growth factor, fibroblast growth factors, connective tissue growth factor, transforming growth factor beta such as TGF- ⁇ 1 through TGF- ⁇ 3, Vascular endothelial growth factor, growth hormone, tissue plasminogen activator or plasminogen activ
  • the concentration of such skin analyte is compared to a reference standard for such skin analyte, e.g., to determine whether such concentrations are above or below normal concentration levels for such subject. In one embodiment, such determination may indicate whether such patient is suffering or at risk for suffering from a skin disorder. In one embodiment, such determination may indicate whether current treatment of a skin disorder is effective, or it may indicate whether a future treatment regimen may be effective.
  • the subject is a mammal such as a human.
  • the method of the present invention may be used on both healthy subjects (e.g., to ensure their skin health) as well as subjects who are inflicted at various stages with a skin disorder, including but not limited to intrinsic skin aging, wrinkles, acne, photodamage, rosacea, scars, hypertrophic scars, keliods, stretch marks or Striae distensae, psoriasis, nutrient status, anti-oxidant status, energy status, oxygen status, eicosanoid staus, leukotriene status, pruritus, ehlers-danlos syndrome, scleroderma, post inflammatory hyperpigmentation, melasma, alopecia, poikiloderma of civatte, viteligo, skin cancers, skin dyschromas, or blotchy pigmentation.
  • a skin disorder including but not limited to intrinsic skin aging, wrinkles, acne, photodamage,
  • the methods of the present invention provide a means for early diagnosis of such skin disorders .
  • the patient and/or doctor thus, can then attempt to treat such disorders at an early stage before such disorders are visually manifested.
  • the method of the present invention may also be used to determine whether a certain skin treatment would be effective or whether a skin treatment is stabilizing, alleviating, and/or curing the skin disorder.
  • a subject can be analyzed to determine whether it has adequate levels of minoxidil synthase in its skin prior to initiation of treatment with minoxidil.
  • Another example is the use of monoclonal antibodies to TNF- ⁇ as a treatment for psoriasis.
  • TNF- ⁇ have been implicated in the presence and severity of psoriatic plaques. Treatment with the monoclonal antibody inhibits the action of TNF- ⁇ and results in the resolution of the plaque. Continued measurement of the ratio of TNF- ⁇ to MABTNF- ⁇ may predict the necessity of treatment in order to maintain the disease in a quiescent state.
  • the use of the present invention would allow measurement of the antigen/antibody level in the skin, which may provide a more accurate assessment of the condition than the same measurement taken from circulating systemic blood.
  • such monitoring using the methods of the present invention may decrease the cost, side effects, and inconvenience of a typical timed regimen, thereby, improving the quality of life of the patient.
  • a skin care composition can be administered to the subject to address any problems identified following the analysis of the skin analytes.
  • a skin care product is administered, e.g., by the subject or a doctor, to said subject to alter the amount of said skin analyte in the skin of the subject.
  • a skin care product is a topical composition comprising cosmetically active agent.
  • a cosmetically active agent is a compound (e.g., a synthetic compound or a compound isolated from a natural source) that has a cosmetic or therapeutic effect on the skin, including, but not limiting to, anti-aging agents, lightening agents, darkening agents such as self-tanning agents, anti-acne agents, shine control agents, anti -microbial agents, anti -inflammatory agents, anti-mycotic agents, anti-parasite agents, anti- cancer agents, agents for photodynamic therapy, steroids, external analgesics, sunscreens, photoprotectors, antioxidants, keratolytic agents, detergents/surfactants, moisturizers, nutrients, amino acids, amino acid derivatives, minerals, plant extracts, animal-derived substances, vitamins, energy enhancers, anti-perspiration agents, astringents, deodorants, hair removers, hair growth stimulators, hair growth retarding agents,
  • the agent is selected from, but not limited to, the group consisting of hydroxy acids, benzoyl peroxide, sulfur resorcinol, ascorbic acid, D- panthenol, hydroquinone , octyl methoxycinnimate, titanium dioxide, octyl salicylate, homosalate, avobenzone, polyphenolics, carotenoids, free radical scavengers, spin traps, retinoids such as retinol and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogens, steroids such as hydrocortisone, 2-dimethylaminoethanol, copper salts such as copper chloride, peptides containing copper such as Cu:Gly-His-Lys, coenzyme Q10, peptides such as those disclosed in PCT Patent Application No.
  • WO 00/15188 lipoic acid, amino acids such a proline and tyrosine, vitamins, lactobionic acid, acetyl-coenzyme A, niacin, riboflavin, thiamin, ribose, electron transporters such as NADH and FADH2 , and other botanical extracts such as aloe vera and legumes such as soy beans, and derivatives and mixtures thereof.
  • the cosmetically active agent will typically be present in the composition of the invention in an amount of from about 0.001% to about 20% by weight of the composition, e.g., about 0.01% to about 10% such as about 0.1% to about 5%.
  • vitamins include, but are not limited to, vitamin A, vitamin Bs such as vitamin B3, vitamin B5, and vitamin B12, vitamin C, vitamin K, and vitamin E and derivatives thereof.
  • hydroxy acids include, but are not limited, to glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid. See, e.g., European Patent Application No. 273,202.
  • antioxidants include but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine) , lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin, glutathione, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide) .
  • water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine)
  • lipoic acid and dihydrolipoic acid resveratrol, lactoferrin, glutathione
  • ascorbic acid and ascorbic acid derivatives e.g., ascorbyl palmitate and ascorbyl polypeptide
  • Oil-soluble antioxidants suitable for use in the compositions of this invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, and ubiquinone.
  • Natural extracts containing antioxidants suitable for use in the compositions of this invention include, but not limited to, extracts containing flavonoids and isoflavonoids and their derivatives (e.g., genistein and diadzein) , extracts containing resveratrol and the like. Examples of such natural extracts include grape seed, green tea, pine bark, and propolis. Other examples of antioxidants may be found on pages 1612-13 of the ICI Handbook.
  • compositions useful in the subject invention include humectants, proteins and polypeptides, amino acids, ion conjugated amino acids preservatives and an alkaline agent. Examples of such agents are disclosed in the ICI Handbook, pp.1650-1667.
  • the compositions of the present invention may also comprise chelating agents (e.g., EDTA) and preservatives (e.g., parabens) . Examples of suitable preservatives and chelating agents are listed in pp. 1626 and 1654-55 of the ICI Handbook.
  • the topical compositions useful herein can contain conventional cosmetic adjuvants, such as dyes, opacifiers (e.g., titanium dioxide), pigments, and fragrances.
  • Skin care products may also be distributed to subjects based upon the knowledge obtained for the measurement of a skin analyte in the subj ect ' s interstitial fluid.
  • a skin care product may be distributed to the subject to alter (e.g., increase or decrease) the amount of the skin analyte in the skin of the subject directly or indirectly.
  • a profile of specific analytes in the skin may be more predictive of a disease or traumatic state of the skin that may require a unique combination of ingredients delivered in a specific regimen.
  • specific skin care products may be distributed to subjects to address the subject's individual needs.
  • "distributing a skin care product” includes the giving, selling, as well as providing a prescription, for a skin care product.
  • retail establishments can use the methods herein to sell skin care products to customers.
  • Doctors such as dermatologists, can use the methods herein to both diagnose subjects who are suffering, or at risk of suffering, from a skin disorder, and provide the subject with a skin care product or a prescription for a skin care product.
  • the following is a description of the extraction and analysis of various skin analytes from human subjects.
  • Other methods of the invention can be practiced in an analogous manner by a person of ordinary skill in the art .
  • interstitial fluid ISF
  • the skin analytes vitamin C, interluekin-l ⁇ (“IL-1A”), and metalloproteinase-1 (“MMP- 1") were measured during the first clinical study (“Study 1") while the analytes vitamin C, immunoglobulin E (“IGE”) , insulin-like growth factor-1 (“IGF-1”), IL-1A, IL-1 receptor antagonist (“IL-1 RA” ) , and MMP-1 were measured in the second clinical study (“Study 2" ) . It is believed that these skin analytes may be predictive of , the level of intrinsic or extrinsic skin aging.
  • Study 1 was conducted with 20 patients during the month of June while Study 2 was conducted with 27 patients during the month of September.
  • subjects were also separated into those who had a high body mass index (BMI > 27) to see if available fluid in the skin made a difference in collection or concentration of recovered analytes .
  • the stratum corneum of the sites from which the ISF was removed were first opened using a laser device which activates a dye on the skin surface as described in U.S. Patent No. 5,885,211.
  • the device was obtained from SpectRx Inc. (Norcross, GA 30071) .
  • the laser made four pores at each collection site. Two collection sites were used in study 1 while four collection sites were used in study 2. These areas were shaven, if necessary, to remove any hair which may interfere with the procedure and then prepped using a skin cleanser prior to poration.
  • a hand held vacuum apparatus was attached to the site using an "A" style harvesting head. The head was attached to the skin with a medical grade adhesive .
  • the sample reservoir in the area over the opening was visually monitored to track the ISF flow rate.
  • ISF was collected into thin- walled medical tubing, which allows for visual fluid quantification.
  • the clear plastic tubing also allowed the researcher to visually assess any sign of redness or irritation and the presence of blood.
  • the ISF collection period lasted between 3 and 6 hours, typically 4 hours.
  • the amount of ISF collected during each of the studies are set forth in Tables 1 and 2, separated by the location of the skin tested. These results indicated that an increase in the number of openings consequently increased the volume of ISF collected as patients in Study 1 received eight openings while those in Study 2 received sixteen openings. Additionally this data suggests that the amount of fluid acquired is site dependent as it was found to be easier to extract fluid from the arm than from the buttock.
  • IL-IA can be measured in as little as 10 microliters of interstitial fluid from skin.
  • Vitamin C was measured using a standard assay described in the Laboratory Procedures Used by the Clinical Chemistry Division, Centers for Disease Control, for the Second Health and Nutrition Examination Survey (HANES II) 1976-1980, published by the U.S. Department of Health and Human Services, Public Health Services, Atlanta, Georgia, pp. 17-19 (1979) .
  • Tables 5 and 6 also indicate that detectable levels of vitamin C were measured in ISF.
  • the results also discovered that the amount of vitamin C in the ISF was not the same as the amount present in serum, thus, indicating that the a serum measurement of vitamin C is not indicative of its concentration within the skin.
  • the amount of vitamin C measured in Study 2 was also different from that measured in Study 1, indicating the possible seasonal effect (e.g., sun exposure) on the concentration of vitamin C in the skin.
  • the other skin analytes were measured in Study 2 using standard ELISA kits: MMP-1 (ELISA Cat # QIA55, Oncogene Research Products, Cambridge MA); Total IgE (ELISA Cat # RE59061, IBL, Hamburg, Germany distributed by KMI Diagnostics) ; Non Extraction IGF-1 (ELISA Cat # DSL-10-2800, Diagnostics Systems Laboratories, Webster TX) ; IL-1 RA (ELISA Cat # DRA00, R&D Systems, Minneapolis, MN) ; IL-IA (ELISA Cat # EH2IL1A, Pierce/Endogen, Rockford, IL) . Tables 7-8 reports on the concentration of these analytes.
  • MMP-1 ELISA Cat # QIA55, Oncogene Research Products, Cambridge MA
  • Total IgE ELISA Cat # RE59061, IBL, Hamburg, Germany distributed by KMI Diagnostics
  • Non Extraction IGF-1 ELISA Cat # DSL-10-2800, Diagnostics Systems Laboratories, Webster TX
  • the results of Study 2 also indicated that sun- protected area had significantly (p ⁇ 0.01) higher levels of IgE, IL-IA, and MMP-1. Also the results revealed that vitamin C supplement significantly increased the concentration of vitamin C as well as IgE, IL-IA, IL-1 RA, and MMP-1 in ISF. The study also indicated that males have significantly higher concentrations of IgE, IGF-1, and IL-1 RA, and women had significantly higher concentration of IL-IA. The study also indicated that subjects with a high BMI had higher concentration of IgE.
  • the following clinical study was performed to demonstrate the concept of application of a bioactive material and the subsequent monitoring of the substance thereafter.
  • the studies included non-smoking, female subjects of good health over the age of 35 years and under the age 55 years with skin type of III or less by the Fitzpatrick Skin classification. Additionally, subjects did not take any vitamin, nutritional or mineral supplement orally or topically. Interstitial fluid was analyzed for Vitamin C in order to identify a specific population of subjects within approximately one standard deviation of the mean of all potential candidates tested. Acceptable subjects were chronologically enrolled in the study following a randomization code describing what treatment would be applied to which dorsal forearm. Treatments included a high and a moderate concentration of Vitamin C in a topical emulsion.
  • Vitamin C levels were measured from an aliquot of fluid acquired from the skin and the serum. ISF was extracted from the dorsal forearm, volar upper arm, and serum at one week ("Week 2") and three weeks after dosing ("Week 4") and two weeks after the cessation of dosing ("Week 6") .
  • ISF was extracted from both the treatment site
  • the ISF was removed using the same procedure described in Example 1 with the device making four pores at each collection site.
  • the ISF collection period lasted between three and six hours, typically four hours.
  • Vitamin C was measured using a standard assay described in the Laboratory Procedures Used by the Clinical Chemistry Division, Centers for Disease Control, for the Second Health and Nutrition Examination Survey (HANES II) 1976-1980, published by the U.S.
  • Results presented in Table 9 demonstrate that application of topical Vitamin C in either high dose or moderate dose modulates the level of Vitamin C at the application site in a dose dependent manner that is significantly different than the placebo that did not contain Vitamin C.
  • the effect was maximal at the first week after therapy was initiated in the high dose treatment group and declined at week four.
  • the moderate dose appeared to stabilize at the concentration achieved during the first week. All doses decreased to approximate baseline values two weeks after ending therapy at week six.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

L'invention concerne un procédé destiné à examiner ou à diagnostiquer la santé dermatologique d'un sujet. Ce procédé consiste: à accéder à un échantillon de fluide interstitiel de la peau du sujet; et à mesurer la quantité d'analyte dermatologique contenue dans l'échantillon. Cette invention concerne également un procédé destiné à traiter la peau d'un sujet et un procédé de distribution d'un produit pour le soin de la peau d'un sujet.
PCT/US2002/011344 2001-05-18 2002-04-05 Procede destine a examiner et a diagnostiquer la sante dermatologique WO2002095418A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02733970A EP1412756A2 (fr) 2001-05-18 2002-04-05 Procede destine a examiner et a diagnostiquer la sante dermatologique
CA002447323A CA2447323A1 (fr) 2001-05-18 2002-04-05 Procede destine a examiner et a diagnostiquer la sante dermatologique

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/920,593 2001-08-01
US09/920,266 2001-08-01
US09/920,136 2001-08-01
US09/920,593 US6840910B2 (en) 2001-08-01 2001-08-01 Method of distributing skin care products
US09/920,136 US6855117B2 (en) 2001-08-01 2001-08-01 Method of treating the skin of a subject
US09/920,266 US6790179B2 (en) 2001-08-01 2001-08-01 Method of examining and diagnosing skin health

Publications (2)

Publication Number Publication Date
WO2002095418A2 true WO2002095418A2 (fr) 2002-11-28
WO2002095418A3 WO2002095418A3 (fr) 2003-05-30

Family

ID=27420646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/011344 WO2002095418A2 (fr) 2001-05-18 2002-04-05 Procede destine a examiner et a diagnostiquer la sante dermatologique

Country Status (1)

Country Link
WO (1) WO2002095418A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101900722A (zh) * 2009-05-25 2010-12-01 希森美康株式会社 组织液中分析物的分析方法和装置及分析药盒和试剂盒

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313258A1 (de) * 1993-04-23 1994-10-27 Beiersdorf Ag Verfahren und Vorrichtung zur meßtechnischen quantitativen Bestimmung der Textur der menschlichen Hautoberfläche durch Registrierung, Wiedergabe und Analysierung von Bildinformationen
US6027496A (en) * 1997-03-25 2000-02-22 Abbott Laboratories Removal of stratum corneum by means of light
WO2000010579A1 (fr) * 1998-08-18 2000-03-02 California Skin Research Institute Detection de facteurs biologiques dans l'epiderme
US6155992A (en) * 1997-12-02 2000-12-05 Abbott Laboratories Method and apparatus for obtaining interstitial fluid for diagnostic tests
JP2000352566A (ja) * 1999-06-10 2000-12-19 Pola Chem Ind Inc 生体状況の鑑別法
JP2001187025A (ja) * 1999-10-22 2001-07-10 Kao Corp 皮膚の健康度評価方法
GB2358706A (en) * 1999-10-22 2001-08-01 Kao Corp An apparatus and method for evaluating skin health
DE10100127A1 (de) * 2001-01-03 2002-10-02 Henkel Kgaa Verfahren zur Bestimmung der Homeostase der Haut
WO2002082093A2 (fr) * 2001-04-02 2002-10-17 Tufts University Procedes permettant de mesurer l'activite antioxydante des lipides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313258A1 (de) * 1993-04-23 1994-10-27 Beiersdorf Ag Verfahren und Vorrichtung zur meßtechnischen quantitativen Bestimmung der Textur der menschlichen Hautoberfläche durch Registrierung, Wiedergabe und Analysierung von Bildinformationen
US6027496A (en) * 1997-03-25 2000-02-22 Abbott Laboratories Removal of stratum corneum by means of light
US6155992A (en) * 1997-12-02 2000-12-05 Abbott Laboratories Method and apparatus for obtaining interstitial fluid for diagnostic tests
WO2000010579A1 (fr) * 1998-08-18 2000-03-02 California Skin Research Institute Detection de facteurs biologiques dans l'epiderme
JP2000352566A (ja) * 1999-06-10 2000-12-19 Pola Chem Ind Inc 生体状況の鑑別法
JP2001187025A (ja) * 1999-10-22 2001-07-10 Kao Corp 皮膚の健康度評価方法
GB2358706A (en) * 1999-10-22 2001-08-01 Kao Corp An apparatus and method for evaluating skin health
DE10100127A1 (de) * 2001-01-03 2002-10-02 Henkel Kgaa Verfahren zur Bestimmung der Homeostase der Haut
WO2002082093A2 (fr) * 2001-04-02 2002-10-17 Tufts University Procedes permettant de mesurer l'activite antioxydante des lipides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
K. BORK ET AL: "Histamine levels in interstitial fluid of lesioned and perilesional skin in patients with chronic idiopathic urticaria" ARCHIVES OF DERMATOLOGICAL RESEARCH, vol. 266, no. 3, 1979, pages 269-276, XP002230076 *
MAILE LAURA A ET AL: "Active and inhibitory components of the insulin-like growth factor binding protein-3 protease system in adult serum, interstitial, and synovial fluid." ENDOCRINOLOGY, vol. 139, no. 12, December 1998 (1998-12), pages 4772-4781, XP002230077 ISSN: 0013-7227 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 15, 6 April 2001 (2001-04-06) & JP 2000 352566 A (POLA CHEM IND INC), 19 December 2000 (2000-12-19) *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 24, 11 May 2001 (2001-05-11) & JP 2001 187025 A (KAO CORP), 10 July 2001 (2001-07-10) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101900722A (zh) * 2009-05-25 2010-12-01 希森美康株式会社 组织液中分析物的分析方法和装置及分析药盒和试剂盒

Also Published As

Publication number Publication date
WO2002095418A3 (fr) 2003-05-30

Similar Documents

Publication Publication Date Title
US6855117B2 (en) Method of treating the skin of a subject
US6790179B2 (en) Method of examining and diagnosing skin health
EP1107690B1 (fr) Deuxieme utilisation therapeutique d'un procede d'apport de particules
CA2317777C (fr) Transport transdermique par sonophorese ameliore
US7004901B2 (en) Method and kit for the transdermal determination of analyte concentration in blood
Portugal-Cohen et al. Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: cytokines, antioxidants and psoriatic skin auto-fluorescence
Korri et al. Increased blood acetate: a new laboratory marker of alcoholism and heavy drinking
US20050053637A1 (en) Personalized cosmetics
CN104471391B (zh) 鉴别具有治疗性皮脂抑制活性的ahr受体的配体的方法以及所述配体
US6840910B2 (en) Method of distributing skin care products
KR102216913B1 (ko) 마이크로니들 패치를 포함하는 최소 침습적 피부보습 정도 평가 키트 및 피부보습 정도 평가를 위한 바이오마커
JP2024026167A (ja) マイクロニードルパッチを含む最小侵襲的皮膚状態の診断キット
WO2002095418A2 (fr) Procede destine a examiner et a diagnostiquer la sante dermatologique
EP1412756A2 (fr) Procede destine a examiner et a diagnostiquer la sante dermatologique
Erel et al. Serum levels of vitamins A, C, and E, β-carotene, selenium, and zinc in patients with Behçet’s disease: a controlled study
Ternowitz Monocyte and neutrophil chemotaxis in psoriasis: Relation to the clinical status and the type of psoriasis
JP3863462B2 (ja) 皮膚疾患および敏感肌の検査方法ならびにその方法に利用するキット
Murthy et al. Electroporation and transcutaneous extraction (ETE) for pharmacokinetic studies of drugs
Al-Wadei et al. Non-genomic inhibitory signaling of β-carotene in squamous cell carcinoma of the lungs
Marques Ex vivo lipid peroxidation profile of the subjects stratum corneum by the HPLC-TBARS-EVSC protocol
El-taweel et al. The Epithelial Cytokeratins 15 and 19 Gene Expression in Non-Segmental Vitiligo Patients under NB-UVB Phototherapy
JP6823428B2 (ja) Ｉｌ−１レセプターアンタゴニスト（ｉｌ−１ｒａ）産生促進組成物
More et al. Skin Sensitivity and Irritation Testing for Transposing Transdermal Drug Delivery System
Sriwiriyanont A Comparison of in Vivo and in Vitro Penetration of All-trans Retinol from Facial Skin Care Products
Mills Jr et al. Assaying for Bioavailability in Acne

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2447323

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002733970

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002733970

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP